Harbin Gloria Pharmaceuticals - Asset Resilience Ratio

Latest as of March 2026: 9.04%

Harbin Gloria Pharmaceuticals (002437) has an Asset Resilience Ratio of 9.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Harbin Gloria Pharmaceuticals current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥284.08 Million

≈ $41.57 Million USD Cash + Short-term Investments

Total Assets

CN¥3.14 Billion

≈ $459.71 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Harbin Gloria Pharmaceuticals's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Harbin Gloria Pharmaceuticals asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Harbin Gloria Pharmaceuticals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Harbin Gloria Pharmaceuticals long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥284.08 Million	9.04%
Total Liquid Assets	CN¥284.08 Million	9.04%

Asset Resilience Insights

Limited Liquidity: Harbin Gloria Pharmaceuticals maintains only 9.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Harbin Gloria Pharmaceuticals Industry Peers by Asset Resilience Ratio

Compare Harbin Gloria Pharmaceuticals's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	Drug Manufacturers - Specialty & Generic	1.01%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%

Annual Asset Resilience Ratio for Harbin Gloria Pharmaceuticals (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Harbin Gloria Pharmaceuticals.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	17.02%	CN¥533.66 Million ≈ $78.09 Million	CN¥3.13 Billion ≈ $458.69 Million	+15.96pp
2024-12-31	1.06%	CN¥30.00 Million ≈ $4.39 Million	CN¥2.83 Billion ≈ $413.40 Million	-0.18pp
2022-12-31	1.24%	CN¥50.56 Million ≈ $7.40 Million	CN¥4.07 Billion ≈ $596.18 Million	-7.93pp
2013-12-31	9.17%	CN¥270.00 Million ≈ $39.51 Million	CN¥2.94 Billion ≈ $430.65 Million	+6.05pp
2012-12-31	3.12%	CN¥80.00 Million ≈ $11.71 Million	CN¥2.56 Billion ≈ $375.28 Million	--

pp = percentage points

About Harbin Gloria Pharmaceuticals

SHE:002437 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.12 Billion

CN¥7.65 Billion CNY

Market Cap Rank

#8404 Global

#1966 in China

Share Price

CN¥3.43

Change (1 day)

+1.18%

52-Week Range

CN¥2.43 - CN¥4.98

All Time High

CN¥11.06